Drug Trial Radar · NCT04662710
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
895
Actual
Start
Dec 30, 2020
Primary completion
Oct 29, 2024
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Eisai Inc.
- First posted
- Dec 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. The primary study hypotheses are that lenvatinib plus pembrolizumab plus chemotherapy is superior to chemotherapy alone for both overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), in participants with programmed cell death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and in all participants.
Conditions
- Advanced/Metastatic Gastroesophageal Adenocarcinoma
Interventions
PembrolizumabBiological
400 mg Q6W by IV infusion
LenvatinibBiological
Administered PO QD, 8 mg induction/20 mg consolidation.
OxaliplatinDrug
130 mg/m\^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m\^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
CapecitabineDrug
1000 mg/m\^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.
Leucovorin (or Levoleucovorin)Drug
Administered by IV infusion at 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
5-FUDrug
400 mg/m\^2 bolus IV infusion followed by 2400 mg/m\^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to ~21 days
- Part 1: Number of Participants With Adverse Events (AEs)Time frame: Up to ~44 months
- Part 1: Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to ~29 months
- Part 2: Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1Time frame: Up to ~41 months
- Part 2: OS in All ParticipantsTime frame: Up to ~41 months
- Part 2: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1Time frame: Up to ~29 months
- Part 2: PFS Per RECIST 1.1 as Assessed by BICR in All ParticipantsTime frame: Up to ~29 months
Locations
177 sites in 24 countries. Site status is shown where the registry gives one.
UCLA Hematology/Oncology - Santa Monica ( Site 0003)
Los Angeles, California
Georgetown University Medical Center ( Site 0009)
Washington D.C., District of Columbia
James Graham Brown Cancer Center ( Site 0017)
Louisville, Kentucky
Johns Hopkins University ( Site 0052)
Baltimore, Maryland
Dana Farber Cancer Center ( Site 0019)
Boston, Massachusetts
UMASS Memorial Medical Center ( Site 0020)
Worcester, Massachusetts
Henry Ford Health System ( Site 0023)
Detroit, Michigan
Cancer and Hematology Centers of Western Michigan ( Site 0025)
Grand Rapids, Michigan
Washington University School of Medicine ( Site 0027)
St Louis, Missouri
Mount Sinai Hospital ( Site 0051)
New York, New York
Memorial Sloan Kettering Cancer Center ( Site 0032)
New York, New York
AHN West Penn Hospital-AHN Esophageal and Lung Institute ( Site 0058)
Pittsburgh, Pennsylvania
Fundacion Favaloro ( Site 0201)
Buenos Aires, Argentina
Hospital Aleman ( Site 0210)
Buenos Aires, Argentina
Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0207)
Buenos Aires, Argentina
CEMIC ( Site 0209)
Buenos Aires, Argentina
Hospital Privado de Cordoba ( Site 0204)
Córdoba, Argentina
IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0202)
Caba, Buenos Aires, Argentina
Instituto Medico Alexander Fleming ( Site 0208)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Nepean Hospital ( Site 2305)
Kingswood, New South Wales, Australia
Wollongong Hospital ( Site 2307)
Wollongong, New South Wales, Australia
Royal Brisbane and Women s Hospital ( Site 2304)
Herston, Queensland, Australia
Hollywood Private Hospital-Medical Oncology ( Site 2308)
Nedlands, Western Australia, Australia
CHU UCL Namur Site de Godinne ( Site 1005)
Yvoir, Namur, Belgium
UZ Gent ( Site 1002)
Ghent, Oost-Vlaanderen, Belgium
UZ Leuven ( Site 1004)
Leuven, Vlaams-Brabant, Belgium
AZ Delta ( Site 1006)
Roeselare, West-Vlaanderen, Belgium
Queen Elizabeth II Health Sciences Centre ( Site 0101)
Halifax, Nova Scotia, Canada
Hamilton Health Sciences - Juravinski Site ( Site 0106)
Hamilton, Ontario, Canada
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0103)
Sherbrooke, Quebec, Canada
Centro Investigación del Cáncer James Lind ( Site 0414)
Temuco, Araucania, Chile
IC La Serena Research ( Site 0410)
La Serena, Coquimbo Region, Chile
Clinica Universidad Catolica del Maule ( Site 0411)
Talca, Maule Region, Chile
Fundacion Arturo Lopez Perez FALP ( Site 0403)
Santiago, Region M. de Santiago, Chile
Clínica San Carlos de Apoquindo Red Salud UC Christus ( Site 0407)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0404)
Santiago, Region M. de Santiago, Chile
Anhui Provincial Hospital ( Site 2415)
Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Sciences ( Site 2403)
Beijing, Beijing Municipality, China
Beijing Cancer Hospital ( Site 2453)
Beijing, Beijing Municipality, China
Fujian Provincial Cancer Hospital ( Site 2408)
Fuzhou, Fujian, China
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.